GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression Corrigendum in /10.3892/ol.2021.12836

Zhang,Zhuoliang; Fang,Xingliang; Xie,Guilin; Zhu,Jinlong

doi:10.3892/ol.2021.12492

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression

Corrigendum in: /10.3892/ol.2021.12836

Authors:
- Zhuoliang Zhang
- Xingliang Fang
- Guilin Xie
- Jinlong Zhu
View Affiliations

Affiliations: Department of General Surgery I, The Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: January 26, 2021 https://doi.org/10.3892/ol.2021.12492
Article Number: 231
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that GATA3 is downregulated in multiple types of tumours, including gastric cancer and osteosarcoma. The aim of this study was to explore whether GATA3 serves as a tumour suppressor to inhibit hepatocellular carcinoma (HCC) development. Tumour tissue specimens and adjacent normal tissue specimens were obtained from 162 patients diagnosed with HCC in the Affiliated Hospital of Shaoxing University from July 2000 to May 2018. The result of the present study demonstrated that GATA3 was downregulated in HCC tumour tissues compared with that of adjacent normal tissues. The expression of GATA3 was also negatively associated with tumour size, TNM stage and lymph node metastasis. Additionally, analysis of the follow‑up data revealed that low GATA3 expression was closely correlated with poor survival. Gain and loss of function analyses revealed that overexpression of GATA3 decreased the ability of proliferation, migration and invasion in HCC cell lines, whereas inhibition of GATA3 promoted the ability of proliferation, migration and invasion. In addition, GATA3 suppressed EMT through the regulation of slug expression. Additionally, slug overexpression attenuated the inhibitory effects of GATA3 overexpression on cancer cell proliferation, migration and invasion. Thus, GATA3 is downregulated in HCC, and suppresses cell proliferation, migration and invasion. Moreover, GATA3 transcriptionally inhibits slug expression, thereby suppressing EMT in HCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
3	Torres HA, Vauthey JN, Economides MP, Mahale P and Kaseb A: Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 65:862–864. 2016. View Article : Google Scholar : PubMed/NCBI
4	Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
5	Chapman BC, Paniccia A, Hosokawa PW, Henderson WG, Overbey DM, Messersmith W, McCarter MD, Gleisner A, Edil BH, Schulick RD, et al: Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. J Am Coll Surg. 224:362–372. 2017. View Article : Google Scholar : PubMed/NCBI
6	Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
7	Hirohashi S and Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci. 94:575–581. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Sugimachi K and Tsuneyoshi M: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol. 14:900–905. 2001. View Article : Google Scholar : PubMed/NCBI
9	Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
10	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ho IC and Pai SY: GATA-3 - not just for Th2 cells anymore. Cell Mol Immunol. 4:15–29. 2007.PubMed/NCBI
12	Simon MC: Gotta have GATA. Nat Genet. 11:9–11. 1995. View Article : Google Scholar : PubMed/NCBI
13	Hosoya T, Maillard I and Engel JD: From the cradle to the grave: Activities of GATA-3 throughout T-cell development and differentiation. Immunol Rev. 238:110–125. 2010. View Article : Google Scholar : PubMed/NCBI
14	Haraguchi T, Miyoshi H, Hiraoka K, Yokoyama S, Ishibashi Y, Hashiguchi T, Matsuda K, Hamada T, Okawa T, Shiba N, et al: GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas. PLoS One. 11:e01565242016. View Article : Google Scholar : PubMed/NCBI
15	Engelsen IB, Stefansson IM, Akslen LA and Salvesen HB: GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumours with high proliferation and poor patient survival. Am J Obstet Gynecol. 199:543.e1–7. 2008. View Article : Google Scholar
16	Peng H, Ke XX, Hu R, Yang L, Cui H and Wei Y: Essential role of GATA3 in regulation of differentiation and cell proliferation in SK-N-SH neuroblastoma cells. Mol Med Rep. 11:881–886. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ma L, Xue W and Ma X: GATA3 is downregulated in osteosarcoma and facilitates EMT as well as migration through regulation of slug. OncoTargets Ther. 11:7579–7589. 2018. View Article : Google Scholar
18	Yin G, Liu Z, Wang Y, Sun L, Wang L, Yao B, Liu R, Chen T, Niu Y and Liu Q: ZNF503 accelerates aggressiveness of hepatocellular carcinoma cells by down-regulation of GATA3 expression and regulated by microRNA-495. Am J Transl Res. 11:3426–3437. 2019.PubMed/NCBI
19	Zheng Y, Wang DD, Wang W, Pan K, Huang CY, Li YF, Wang QJ, Yuan SQ, Jiang SS, Qiu HB, et al: Reduced expression of uroplakin 1A is associated with the poor prognosis of gastric adenocarcinoma patients. PLoS One. 9:e930732014. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Cai X, Zhu H and Li Y: PKCζ, MMP-2 and MMP-9 expression in lung adenocarcinoma and association with a metastatic phenotype. Mol Med Rep. 16:8301–8306. 2017. View Article : Google Scholar : PubMed/NCBI
22	Zhao Y, Zhou FL, Li WP, Wang J and Wang LJ: Slit2 Robo1 signaling promotes the adhesion, invasion and migration of tongue carcinoma cells via upregulating matrix metalloproteinases 2 and 9, and downregulating E cadherin. Mol Med Rep. 14:1901–1906. 2016. View Article : Google Scholar : PubMed/NCBI
23	Liao TT and Yang MH: Revisiting epithelial-mesenchymal transition in cancer metastasis: The connection between epithelial plasticity and stemness. Mol Oncol. 11:792–804. 2017. View Article : Google Scholar : PubMed/NCBI
24	Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM and Kleer CG: Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 65:11259–11264. 2005. View Article : Google Scholar : PubMed/NCBI
25	Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L, Zhou X, Wang Y, Su D, Gao J, et al: Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell. 27:822–836. 2015. View Article : Google Scholar : PubMed/NCBI
26	Shan L, Li X, Liu L, Ding X, Wang Q, Zheng Y, Duan Y, Xuan C, Wang Y, Yang F, et al: GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation. Oncogene. 33:3205–3216. 2014. View Article : Google Scholar : PubMed/NCBI
27	Takai M, Terai Y, Kawaguchi H, Ashihara K, Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M, et al: The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
28	Wei S, Zhong L, Wang X and Zhang W: Low expression of GATA3 promotes cell proliferation and metastasis in gastric cancer. Cancer Manag Res. 9:769–780. 2017. View Article : Google Scholar : PubMed/NCBI
29	Guan Y, Li W, Hou Z, Han Q, Lan P, Zhang J, Tian Z and Zhang C: HBV suppresses expression of MICA/B on hepatoma cells through up-regulation of transcription factors GATA2 and GATA3 to escape from NK cell surveillance. Oncotarget. 7:56107–56119. 2016. View Article : Google Scholar : PubMed/NCBI